American Century Companies
AIMT

American Century Companies’s Aimmune Therapeutics AIMT Stock Holding History

American Century Companies’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-295,896
Closed -$4.94M – 1887
2020
Q2 		$4.94M Buy
295,896
+171,509
+138% +$2.91M ﹤0.01% 777
2020
Q1 		$1.79M Sell
124,387
-87,507
-41% -$2.24M ﹤0.01% 861
2019
Q4 		$7.09M Buy
211,894
+79,101
+60% +$2.21M 0.01% 752
2019
Q3 		$2.78M Sell
132,793
-27,638
-17% -$564K ﹤0.01% 919
2019
Q2 		$3.34M Buy
160,431
+26,201
+20% +$539K ﹤0.01% 920
2019
Q1 		$3M Sell
134,230
-493
-0.4% -$11.6K ﹤0.01% 927
2018
Q4 		$3.22M Sell
134,723
-10,640
-7% -$275K ﹤0.01% 898
2018
Q3 		$3.97M Buy
145,363
+24,531
+20% +$694K ﹤0.01% 909
2018
Q2 		$3.25M Sell
120,832
-745
-0.6% -$22.8K ﹤0.01% 934
2018
Q1 		$3.87M Buy
121,577
+34,062
+39% +$1.2M ﹤0.01% 889
2017
Q4 		$3.31M Sell
87,515
-265
-0.3% -$8.55K ﹤0.01% 917
2017
Q3 		$2.18M Sell
87,780
-8,774
-9% -$189K ﹤0.01% 1019
2017
Q2 		$1.99M Sell
96,554
-11,638
-11% -$222K ﹤0.01% 1036
2017
Q1 		$2.35M Sell
108,192
-500
-0.5% -$10.3K ﹤0.01% 1017
2016
Q4 		$2.22M Buy
108,692
+6,659
+7% +$136K ﹤0.01% 1024
2016
Q3 		$1.53M Buy
102,033
+3,772
+4% +$50.9K ﹤0.01% 1101
2016
Q2 		$1.06M Buy
98,261
+4,201
+4% +$57.1K ﹤0.01% 1129
2016
Q1 		$1.27M Buy
94,060
+3,855
+4% +$60.1K ﹤0.01% 1073
2015
Q4 		$1.66M Buy
90,205
+7,913
+10% +$146K ﹤0.01% 1048
2015
Q3 		$2.08M Buy
+82,292
New +$1.92M ﹤0.01% 1008

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

American Century Companies's AIMT Position: Q3 2020 in Review

American Century Companies sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 295,896 shares — an estimated $4.94M sold.

American Century Companies first reported a position in AIMT in Q3 2015 and held it in 20 quarters. The position peaked at $7.09M in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • American Century Companies reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • American Century Companies sold 295,896 Aimmune Therapeutics shares in Q3 2020, an estimated $4.94M.
  • American Century Companies first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 20 quarters.
  • American Century Companies's Aimmune Therapeutics position peaked at $7.09M in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on American Century Companies's 13F filing for Q3 2020, filed 13 Nov 2020.